BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 2465574)

  • 21. Novel investigative approaches for advanced renal cell carcinoma.
    Berg WJ; Divgi CR; Nanus DM; Motzer RJ
    Semin Oncol; 2000 Apr; 27(2):234-9. PubMed ID: 10768602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Guideline 'Renal cell carcinoma'].
    Mulders PF; Brouwers AH; Hulsbergen-van der Kaa CA; van Lin EN; Osanto S; de Mulder PH
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):376-80. PubMed ID: 18380384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic therapy of metastatic renal cell carcinoma.
    Vugrin D
    Semin Nephrol; 1987 Jun; 7(2):152-62. PubMed ID: 2442806
    [No Abstract]   [Full Text] [Related]  

  • 25. Adjuvant therapy for renal cell carcinoma.
    Jacobsohn KM; Wood CG
    Semin Oncol; 2006 Oct; 33(5):576-82. PubMed ID: 17045086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multimodality treatment of metastatic renal cell carcinoma.
    Mickisch GH
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):681-5. PubMed ID: 12503214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Outcome of patients in metastatic renal cell carcinoma with or without embolization].
    Masuda F; Nakada J; Takasaka S; Hishinuma H
    Hinyokika Kiyo; 1987 Sep; 33(9):1354-6. PubMed ID: 3434491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
    van Herpen CM; de Mulder PH
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatments for metastatic kidney cancer.
    Mancuso A; Sternberg CN
    Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic renal cell carcinoma: many treatment options, one patient.
    Rini BI
    J Clin Oncol; 2009 Jul; 27(19):3225-34. PubMed ID: 19470934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The medical treatment of renal cancer in adults].
    Sculier JP
    Rev Med Brux; 1989 May; 10(5):190-6. PubMed ID: 2662317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 35. [Long-term results of endovascular treatment of metastatic renal cell cancer].
    Granov AM; Gorelov AI; Shumskiĭ IA; Polikarpov AA; Shkol'nik MI; Vorob'ev MI; Karelin MI
    Vestn Rentgenol Radiol; 1999; (6):20-3. PubMed ID: 10714226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
    Shaheen PE; Bukowski RM
    Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
    Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.
    Wood CG; Margulis V
    Cancer; 2009 May; 115(10 Suppl):2355-60. PubMed ID: 19402066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.